Fulgent Genetics
360Dx Top 30 Slides 5 Percent in March
Of the 30 companies, three saw their stock prices increase, 26 saw their share prices decline, and one company's share price remained virtually flat month over month.
Fulgent Genetics Q4 Core Revenues Rise 14 Percent, Beat Estimates
Core revenues for full-year 2024 grew 7 percent to $281.2 million.
Top Five Articles on 360Dx Last Week: Becton Dickinson's Spinoff Plans; More
Last week, readers were most interested in a story about BD's plan to separate its Biosciences and Diagnostics Solutions business by the end of 2026.
Foundation Medicine, Fulgent Genetics Partner to Launch Germline Testing in US
The Foundation Medicine next-generation sequencing-based panels use Fulgent's technology platform and will analyze genes associated with hereditary cancers.
Mixed Month for Diagnostics Stocks as 360Dx Top 30 Ticks up 1 Percent in November
Out of the 30 companies tracked by 360Dx, 13 saw their share prices increase, while 17 saw their stock prices decline.
Aug 2, 2024
Fulgent Genetics' Q2 Revenues Rise 5 Percent
Feb 28, 2024
Fulgent Genetics Q4 Core Revenues Rise 21 Percent
Nov 3, 2023
Fulgent Genetics Core Revenues Rise 17 Percent
Aug 4, 2023
Fulgent Genetics Core Revenues Jump 48 Percent
Jun 1, 2023
360Dx Top 30 Drops 6 Percent in May
Sep 1, 2022
360Dx Top 30 Tumbles in August
Apr 21, 2022